MIRA INFORM REPORT

 

 

Report Date :

03.04.2014

 

IDENTIFICATION DETAILS

 

Name :

FERMENTA BIOTECH LIMITED (w.e.f. 10.05.2000)

 

 

Formerly Known As :

FERMENTAPHARMA BIODIL LIMITED

 

 

Registered Office :

C/O Duphar-Interfran Limited Complex, Opposite Vidyapeeth, S.V. Road, Ghodbunder Road, Majiwada, Thane (West) - 400610, Maharashtra

 

 

Country :

India

 

 

Financials (as on) :

31.03.2013

 

 

Date of Incorporation :

11.07.1986

 

 

Com. Reg. No.:

11-134021

 

 

Capital Investment / Paid-up Capital :

Rs. 181.928 Millions

 

 

CIN No.:

[Company Identification No.]

U99999MH1986PLC134021

 

 

PAN No.:

[Permanent Account No.]

AAACF2503N

 

 

Legal Form :

A Closely Held Public Limited Liability Company

 

 

Line of Business :

Manufacturer, Exporter and Marketing of Chemicals, Bulk Drugs and Enzymes.

 

 

No. of Employees :

500 (Approximately)

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba (43)

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

USD 2800000

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

Slow but correct

 

 

Litigation :

Clear

 

 

Comments :

Subject is a subsidiary of “DIL LIMITED”, INDIA. It is an established company having satisfactory track record.

 

There appears drastic dip in profit of the company during financial year 2013.

 

However, the rating rakes in to consideration managerial and financial support that company receives from its parent company and decent general financial position.

 

Trade relations are fair. Business is active. Payment terms are reported to be slow but correct.

 

The company can be considered for business dealings at usual trade terms and condition.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – December 1, 2013

 

Country Name

Previous Rating

(30.09.2013)

Current Rating

(01.12.2013)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

INDIAN ECONOMIC OVERVIEW

 

India’s current account deficit for the fiscal third quarter ended September 2013 narrowed to $4.2 billion or 0.9 % of the gross domestic product from $31.9 billion or 6.5 % of GDP a year earlier, thanks to a pick-up in exports and moderation in gold imports. Manufacturing activity and new orders in India showed their strongest growth in a year in February. The news comes as a relief after data showed Asia’s third largest economy grew by a slower-than-expected 4.7 % annually in the three months through December. The HSBC Manufacturing Purchasing Managers’ Index which gauges the business activity of India’s factories but not its’ utilities, rose to 52.5 in February, its highest in a year from 51.4 in January. Overall new orders for factory goods which rose to a one-year high of 54.9 contributed to the surge. China has emerged as India’s biggest trading partner in the current financial year replacing the United Arab Emirates and pushing it to the third spot. India-China trade has reached $49.5 billion with a 8.7 % share in India’s total trade. The US comes second at $46 billion with 8.1 % share during the first nine months of the current financial year.

 

The Reserve Bank of India has granted an additional nine months to the public to exchange currency notes printed before 2005 including Rs 500 and Rs 1,000 denominations, pushing the deadline to January 1, 2015. A day before dates for the Lok Sabha polls were announced, the government decided to hike interest rates on fixed deposit schemes offered by post offices up to 0.2 per cent. The new rates will be effective April, 1. The Supreme Court will resume hearing on March, 11 Nokia’s appeal against a ruling over transferring ownership of its local mobile phones plant which is the subject of a tax dispute to Microsoft Corp.

 

In the last days of the current Government, another scam has surfaced. The defence ministry has ordered a probe into Hindustan Aeronautics Limited’s contracts from Britain’s Rolls-Royce Holdings worth at least $ 1.2 billion. The Central Bureau of Investigation will look into allegations that over $80 million was paid in kickbacks in a deal signed in 2011. India has asked Boeing Co. to find a solution for problems with state-owned Air India’s 787 Dreamliners. The aircraft has experienced a series of malfunctions since its debut in 2011.

 

EXTERNAL AGENCY RATING

 

Rating Agency Name

CRISIL

Rating

Long Term Rating = BBB-

Rating Explanation

Moderate degree of safety and moderate credit risk

Date

05.02.2013

 

Rating Agency Name

CRISIL

Rating

Short Term Rating = A3+

Rating Explanation

Moderate degree of safety and high credit risk

Date

05.02.2013

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

 

INFORMATION PARTED BY

 

Name :

Mr. Suresh Nair

Designation :

Account Executive

Contact No.:

91-22-66230827

Date :

01.04.2014

 

 

LOCATIONS

 

Registered Office/ Administrative :

C/O Duphar-Interfran Limited Complex, Opposite Vidyapeeth, S.V. Road, Ghodbunder Road, Majiwada, Thane (West) - 400610, Maharashtra, India

Tel. No.:

91-22-67980888/ 800 / 66230827

Mobile No.:

91-9930128326 (Mr. Dilip)

Fax No.:

91-22-67980999/ 67980899

E-Mail :

info@fermentabiotech.com

dilip.peswani@fermentabiotech.com

fermenta@fermentabiotech.com

Website :

www.fermentabiotech.com

Location:

Owned

 

 

Factory 1 :

Village Takoli, P. O. Nagwain, District Mandi – 175121, Himachal Pradesh, India

Tel. No.:

91-1905-287246/ 48/ 49

Fax No.:

91-1905-287250

E-mail:

fblmandi@fermentabiotech.com

 

 

Factory 2 :

Plot No. Z109, B and C, Dahej SEZ, Village Dahej, Taluka - Vagara, Bharuch – 392130, Gujarat, India 

 

 

DIRECTORS

 

As on 24.09.2013

 

Name :

Mr. Satish Varma Azad Nadimpally

Designation :

Managing director

Address :

Flat No. 1104, Quiscent Heights, Mindspace Link Road, Malad (West), Mumbai - 400064, Maharashtra, India

Date of Birth/Age :

21.03.1970

Qualification:

Computer Science

Date of Appointment :

04.10.2004

PAN No.:

AAPPV6580K

DIN No.:

00003255

 

 

Name :

Mr. Krishna Vasantkumar Datla

Designation :

Director

Address :

42 – B, Dhananjay Presidency CHS JVPD Scheme, Juhu, Vile Parle, Mumbai-400049, Maharashtra, India

Date of Birth/Age :

17.12.1980

Qualification:

B com

Date of Appointment :

01.02.2002

PAN No.:

AEIPD5499Q

DIN No.:

00003247

 

 

Name :

Mr. Rajendra Balkrishna Gaitonde

Designation :

Whole-time director

Address :

505  Santoor Society, Lokpuram, Thane (West) - 400610, Maharashtra, India

Date of Birth/Age :

01.06.1962

Qualification:

BSc in Chemical Technology from UDCT Mumbai

Date of Appointment :

04.10.2004

PAN No.:

AEHPG9235N

DIN No.:

00003269

 

 

Name :

Mrs. Anupama Vasantkumar Datla

Designation :

Whole-time director

Address :

A/802, Aditya Samarth, Ramdas Marg, Juhu Scheme, Mumbai – 400049,  Maharashtra, India

Date of Birth/Age :

12.06.1978

Qualification :

Post Graduate in Biotechnology Science Graduate from The Boston College

Date of Appointment :

29.03.2007

PAN No.:

AEFPD0595N

DIN No.:

00217027

 

 

Name :

Mr. Sanjay Ramakant Buch

Designation :

Director

Address :

7/31, Bandra Sona CHS. Complex, Krishna Chandra Marg, Bandra (West), Mumbai – 400050, Maharashtra, India

Date of Birth/Age :

26.09.1968

Qualification:

B A Hons Economics

Date of Appointment :

22.01.2010

PAN No.:

AAPPB5842A

DIN No.:

00391436

 

 

Name :

Mr. Peter John Bains

Designation :

Director

Address :

Hutchins Barn, Forty Green Road, Knotty Green, HP9IXL, Beaconsfield, United Kingdom - 76152

Date of Birth/Age :

26.07.1957

Qualification:

BSc Combined Hons . Physiology/Zoology Sheffield University

Date of Appointment :

19.03.2010

DIN No.:

00430937

 

 

Name :

Mr. Viswanath Venkata Subrahmanya Anjaneya Chibrolu

Designation :

Director

Address :

Flat No. 302, Chaitanya Estates, Moti Nagar, X Road, Hyderabad – 500018, Andhra Pradesh, India

Date of Birth/Age :

12.08.1969

Qualification:

MBA from IIM Lucknow

Date of Appointment :

17.01.2011

DIN No.:

01556254

 

 

Name :

Mr. Tirunelveli Padmanabhan Devarajan

Designation :

Alternate director

Address :

10.03.152 (New No 38 ST No 2) East, Marredpally, Secunderabad – 500026, Andhra Pradesh, India

Date of Birth/Age :

28.03.1964

Qualification:

Chemical Engineer and Post Graduate Degree in Management from IIM Ahmedabad

Date of Appointment :

14.03.2011

DIN No.:

03473633

 

 

KEY EXECUTIVES

 

Name :

Mr. Sanjay Prakash Basantani

Designation :

Secretary

Address :

601, Prairie Tower No. 5, Vasant Lawans, Near Majiwada Naka, Thane (West), Mumbai – 400601, Maharashtra, India

Date of Birth/Age :

29.07.1979

Date of Appointment :

03.09.2012

PAN No.:

AKHPB9796R

 

 

Name :

Mr. Suresh Nair

Designation :

Account Executive

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As on 24.09.2013

 

Names of Shareholders

 

No. of Shares

V. K. Datla

 

12

D. G. Rajan

 

12

O. Swaminatha Reddy

 

12

DIL Limited, India

 

12762464

V. R. Investment and Finance Private Limited, India

 

15000

D. Rajeshwari

 

85338

Govind Desai and Mr. Gunanath Govind Desai

 

2500

Govind Desai and Mr. Damodar Govind Desai

 

1000

Shaila G. Desai and Mr. Damodar Govind Desai

 

1500

S. Krishnan

 

10

S C Uniyal

 

10

Preeti Thakkar

 

3012

Dupen Laboratories Private Limited, India

 

100000

Kumar Subrmanian

 

10

S Raman

 

10

Prashant Kutty

 

20

DVK Investments Private Limited, India

 

87024

K H Kashid

 

10

Krishna Datla Jointly Mr. Rajeshwari Datla

 

27000

Satish Varma

 

10

Allegro Corporate Financial Advisors Private Limited, India

 

789474

Fermenta Biotech Limited ESOP Trust, India

 

488334

Srikant Sharma

 

10

Evolvence India Life Science Fund LLC, Mauritius

 

3830072

Total

 

18192844

 

As on 24.09.2013

Equity Share Break up (Percentage of Total Equity)

 

Category

Percentage

Foreign holdings( Foreign institutional investor(s), Foreign companie(s) Foreign financial institution(s), Non-resident Indian(s) or Overseas Corporate bodies or Others

21.05

Bodies corporate

75.60

Directors or relatives of Directors

0.64

Other top fifty shareholders

2.71

Total

100.00

 

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer, Exporter and Marketing of Chemicals, Bulk Drugs and Enzymes.

 

 

Products :

Item Code No.

Product Description

29361000

Vitamin D3 40 MIU

23099020

VIT.D3 10MIU OIL

29331100

Phenyremadol HCL

30049032

Silicon Powder

39069000

Fermsept (D1 Type)

35079069

FERMASE PS 150

 

 

Exports :

 

Products :

Finished Goods

Countries :

  • Europe
  • USA
  • China

 

 

Imports :

 

Products :

Raw Materials

Countries :

Europe

 

 

Terms :

 

Selling :

L/C / Credit

 

 

Purchasing :

L/C / Credit

 

 

GENERAL INFORMATION

 

Customers :

End Users

 

 

No. of Employees :

500 (Approximately)

 

 

Bankers :

Union Bank of India, Ghodbunder Road Branch, Solitaire Tower, Manpada, Ghodbunder Road, Thane – 400607, Maharashtra, India

Tel. No.:91-22-25890025

 

 

Facilities :

(Rs. In Millions)

Secured Loan

As on

31.03.2013

As on

31.03.2012

Long-term borrowings

 

 

Rupee term loans from banks

129.039

185.687

Rupee term loans from others

17.583

0.000

Loans taken for fixed assets

2.305

4.913

Short-term borrowings

 

 

Working capital loans from banks

215.407

125.927

Total

364.334

316.527

 

 

 

Banking Relations :

---

 

 

Auditors :

 

Name :

S.R. Batliboi and Associates

Chartered Accountants

Address :

14th Floor, The Ruby, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400028, Maharashtra, India

PAN No.:

AABFS3421N

 

 

Holding Company :

DIL Limited

 

 

Enterprises which are owned, or have significant influence of or are partners with Key Management personnel and their relatives

  • Dupen Laboratories Private Limited
  • Lacto Cosmetics (Vapi) Private Limited

 

 

 

Subsidiary Company :

  • Fermenta Biotech (UK) Limited
  • G.I. Biotech Private Limited

 

 

CAPITAL STRUCTURE

 

As on 24.09.2013

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

20000000

Equity Shares

Rs.10/- each

Rs.200.000 Millions

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

18192844

Equity Shares

Rs.10/- each

Rs.181.928 Millions

 

 

 

 

 


 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2013

31.03.2012

31.03.2011

I.              EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

181.928

181.928

181.928

(b) Reserves & Surplus

527.483

516.373

410.035

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

0.000

Total Shareholders’ Funds (1) + (2)

709.411

698.301

591.963

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

148.927

190.600

102.170

(b) Deferred tax liabilities (Net)

16.315

0.633

0.882

(c) Other long term liabilities

0.000

0.000

0.000

(d) long-term provisions

15.555

15.271

14.955

Total Non-current Liabilities (3)

180.797

206.504

118.007

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

248.657

141.677

71.344

(b) Trade payables

146.055

124.183

79.359

(c) Other current liabilities

112.166

58.041

29.911

(d) Short-term provisions

2.034

6.482

9.434

Total Current Liabilities (4)

508.912

330.383

190.048

 

 

 

 

TOTAL

1399.120

1235.188

900.018

 

 

 

 

II.            ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

784.479

544.069

266.075

(ii) Intangible Assets

24.816

34.714

22.169

(iii) Capital work-in-progress

3.693

54.511

137.794

(iv) Intangible assets under development

13.049

8.707

0.000

(b) Non-current Investments

18.662

18.662

18.662

(c) Deferred tax assets (net)

0.000

0.000

0.000

(d)  Long-term Loan and Advances

14.709

43.561

57.571

(e) Other Non-current assets

0.250

0.843

0.214

Total Non-Current Assets

859.658

705.067

502.485

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

0.000

0.000

0.000

(b) Inventories

245.005

208.901

104.537

(c) Trade receivables

250.046

230.963

155.922

(d) Cash and cash equivalents

9.699

60.438

103.605

(e) Short-term loans and advances

28.733

29.819

33.469

(f) Other current assets

5.979

0.000

0.000

Total Current Assets

539.462

530.121

397.533

 

 

 

 

TOTAL

1399.120

1235.188

900.018

 


 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2013

31.03.2012

31.03.2011

 

SALES

 

 

 

 

 

Income

1000.244

1014.108

644.415

 

 

Other Income

17.492

38.850

11.327

 

 

TOTAL                                     (A)

1017.736

1052.958

655.742

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Cost of Materials Consumed

422.384

389.287

207.798

 

 

Purchases of Stock-in-Trade

12.150

10.403

0.553

 

 

Changes in inventories of finished goods, work-in-progress and Stock-in-Trade

(27.621)

(16.138)

(25.506)

 

 

Employees benefits expense

157.412

136.989

101.749

 

 

Other expenses

295.523

299.739

198.963

 

 

TOTAL                                     (B)

859.848

820.280

483.557

 

 

 

 

 

Less

PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)     (C)

157.888

232.678

172.185

 

 

 

 

 

Less

FINANCIAL EXPENSES                                    (D)

52.351

39.840

19.148

 

 

 

 

 

 

PROFIT BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                       (E)

105.537

192.838

153.037

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                     (F)

71.131

60.149

29.473

 

 

 

 

 

 

PROFIT BEFORE TAX (E-F)                              (G)

34.406

132.689

123.564

 

 

 

 

 

Less

TAX                                                                  (H)

23.296

26.351

29.108

 

 

 

 

 

 

PROFIT AFTER TAX (G-H)                                (I)

11.110

106.338

94.456

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

326.156

219.818

132.362

 

 

 

 

 

Less

TRANSFERRED TO CAPITAL REDEMPTION RESERVE

0.000

0.000

7.000

 

 

 

 

 

 

BALANCE CARRIED TO THE B/S

337.266

326.156

219.818

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

 

 

 

 

 

FOB Value of Export

NA

782.053

443.449

 

 

Freight and insurance on exports

NA

21.813

18.402

 

TOTAL EARNINGS

NA

803.866

461.851

 

 

 

 

 

 

IMPORTS

 

 

 

 

 

Raw Materials

NA

NA

76.117

 

 

Stores & Spares

NA

NA

0.173

 

 

Capital Goods

NA

NA

4.661

 

TOTAL IMPORTS

NA

NA

80.951

 

 

 

 

 

 

Earnings Per Share (Rs.)

0.61

5.85

6.64

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2013

31.03.2012

31.03.2011

PAT / Total Income

(%)

1.09

10.10

14.40

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

3.44

13.08

19.17

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

2.52

11.51

16.62

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.05

0.19

0.21

 

 

 

 

 

Debt Equity Ratio

(Total Debt /Networth)

 

0.56

0.48

0.29

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

1.06

1.60

2.09

 

 

FINANCIAL ANALYSIS

[all figures are in Rupees Millions]

 

DEBT EQUITY RATIO

 

Particular

31.03.2011

31.03.2012

31.03.2013

 

(Rs. In Millions)

(Rs. In Millions)

(Rs. In Millions)

Share Capital

181.928

181.928

181.928

Reserves & Surplus

410.035

516.373

527.483

Net worth

591.963

698.301

709.411

 

 

 

 

long-term borrowings

102.170

190.600

148.927

Short term borrowings

71.344

141.677

248.657

Total borrowings

173.514

332.277

397.584

Debt/Equity ratio

0.293

0.476

0.560

 

 

YEAR-ON-YEAR GROWTH

 

Year on Year Growth

31.03.2011

31.03.2012

31.03.2013

 

(Rs. In Millions)

(Rs. In Millions)

(Rs. In Millions)

Sales

644.415

1014.108

1000.244

 

 

57.369

(1.367)

 

 

NET PROFIT MARGIN

 

Net Profit Margin

31.03.2011

31.03.2012

31.03.2013

 

(Rs. In Millions)

(Rs. In Millions)

(Rs. In Millions)

Sales

644.415

1014.108

1000.244

Profit

94.456

106.338

11.110

 

14.66%

10.49%

1.11%

 

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

Yes

9]

Name of person contacted

Yes

10]

Designation of contact person

Yes

11]

Turnover of firm for last three years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

----------------------

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

Yes

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

Yes

20]

Export / Import details (if applicable)

Yes

21]

Market information

----------------------

22]

Litigations that the firm / promoter involved in

----------------------

23]

Banking Details

Yes

24]

Banking facility details

Yes

25]

Conduct of the banking account

----------------------

26]

Buyer visit details

----------------------

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

Yes

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

Yes

32]

PAN of Proprietor/Partner/Director, if available

Yes

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

Yes

 

 

BACKGROUND

 

Subject is a public company domiciled in India and incorporated under the Companies Act, 1956. The Company is engaged in the business of manufacturing and marketing of chemicals, bulk drugs enzymes, pharmaceutical formulations and Environmental solution products. The Company caters to both domestic and international markets.

 

RESULTS FROM OPERATIONS

 

In the year, the Company reported a total revenue from operations of Rs.1017.736 Millions (previous year Rs.1052.958 Millions)

 

Profit before tax for the year is Rs. 34.406 Millions (previous year Rs. 132.689 Millions) and the profit after tax was Rs.11.110 Millions (previous year Rs.106.338 Millions).

 

 

MANAGEMENT DISCUSSION AND ANALYSIS

 

GLOBAL ECONOMY

 

Global economic growth hovered around 3.2 percent in 2012, lower than 3.9% in 2011. The United States, the largest economy, posted better numbers (2.3% in 2012 against 1.8% in 2011). The eurozone reported a negative growth of 0.4% and China’s growth slowed from 9.3% to 7.8%. The global economic growth is expected to recover to 3.3 percent in 2013 and 4 percent in 2014; developing economies are expected to drive global growth (around 5.25 percent in 2013 and 5.75 percent in 2014, according to IMF, April 2013).

 

 

INDIAN ECONOMY

 

In 2012-13, the Indian economy reported 5% growth, its lowest in a decade on account of a poor performance of its manufacturing, agriculture and service sectors. An erratic monsoon and drought-like situation in many parts affected the performance of its agriculture sector; manufacturing growth declined from 2.7 percent to 1.9 percent on account of a weakness in industry (mining and quarrying, manufacturing, electricity, gas and water supply, and construction) at 3.1%. The growth in the services sector was a low 6.6% in 2012-13 as against 8.2% in 2011-12. This weakness extended into government finances: the fiscal deficit for 2012-13 was estimated at 5.2% of GDP and trade deficit touched an unprecedented $190.9 bn in 2012-13 ($183.3 bn in 2011-12).

 

 

EXPORTS

 

Exports have been the cornerstone of growth of the Indian pharma industry. The positive trend in the realm of formulation exports is expected to continue, with 14-16 per cent CAGR envisaged between 2012-13 and 2017-18. Over the next five years, drugs with sales of more than $100 billion are expected to lose patent exclusivity. Healthcare expenditure is rising the world over, the steepest being in the developed markets of the US and Europe. With India’s competitiveness and advanced procedural chemistry skills, Indian players are well-placed to tap into this opportunity and increase their generics presence.

 

Healthcare reforms initiated by the US government, aimed primarily at reducing healthcare spending and extending public healthcare to a larger proportion of the population, are expected to continue driving generics growth. However, the worsening debt crisis in the eurozone is forcing many European governments to cut spending. Although incentives for substituting costly patented drugs with low-cost alternatives will boost the demand for generic drugs, price cuts are becoming increasingly prevalent in the region, impacting innovator and generic drugs.

 

 

UNSECURED LOAN

Rs. In Millions

Particular

As on

31.03.2013

As on

31.03.2012

Short-term borrowings

 

 

Loans and advances from others

33.250

15.750

Total

33.250

15.750

 

 

 

INDEX OF CHARGES

 

S.No.

Charge ID

Date of Charge Creation/Modification

Charge amount secured

 

Charge Holder

Address

Service Request Number (SRN)

1

10369623

18/07/2012

20,000,000.00

UNION BANK OF INDIA

GHODBUNDER ROAD BRANCH, SOLITAIRE TOWER, MANPADA, GHODBUNDER ROAD,, THANE, MAHARASHTRA - 400607, INDIA

B45355302

2

10373704

16/07/2012

35,000,000.00

SIEMENS FINANCIAL SERVICES PRIVATE LIMITED

130, PANDURANG BUDHKAR MARG, WORLI, MUMBAI, MAHARASHTRA - 400018, INDIA

B56909914

3

10311976

28/09/2012 *

100,000,000.00

UNION BANK OF INDIA

GHODBUNDER ROAD BRANCH, SOLITAIRE TOWER, MANPADA, GHODBUNDER ROAD,, THANE, MAHARASHTRA - 400607, INDIA

B60376118

4

10311912

28/09/2012 *

60,000,000.00

UNION BANK OF INDIA

GHODBUNDER ROAD BRANCH, SOLITAIRE TOWER, MANPADA, GHODBUNDER ROAD,, THANE, MAHARASHTRA - 400607, INDIA

B60376787

5

10311913

22/09/2011

10,000,000.00

UNION BANK OF INDIA

GHODBUNDER ROAD BRANCH, SOLITAIRE TOWER, MANPADA, GHODBUNDER ROAD,, THANE, MAHARASHTRA - 400607, INDIA

B23194665

6

10330267

09/10/2012 *

459,700,000.00

UNION BANK OF INDIA

GHODBUNDER ROAD BRANCH, SOLITAIRE TOWER, MANPADA, GHODBUNDER ROAD,, THANE, MAHARASHTRA - 400607, INDIA

B60379674

7

10254874

15/11/2010

200,000,000.00

UNION BANK OF INDIA

GHODBUNDER ROAD BRANCH, SOLITAIRE TOWER, MANPADA, GHODBUNDER ROAD,, THANE, MAHARASHTRA - 400607, INDIA

B00116210

8

10200372

21/01/2010

30,000,000.00

UNION BANK OF INDIA

GHODBUNDER ROAD BRANCH, SOLITAIRE TOWER, MANPADA, GHODBUNDER ROAD,, THANE, MAHARASHTRA - 400607, INDIA

A78743846

9

10136274

28/09/2012 *

60,000,000.00

UNION BANK OF INDIA

GHODBUNDER ROAD BRANCH, SOLITAIRE TOWER, MANPADA, GHODBUNDER ROAD,, THANE, MAHARASHTRA - 400607, INDIA

B60377413

10

10061101

28/09/2012 *

460,300,000.00

UNION BANK OF INDIA

GHODBUNDER ROAD BRANCH, SOLITAIRE TOWER, MANPADA, GHODBUNDER ROAD,, THANE, MAHARASHTRA - 400607, INDIA

B60378197

 

* Date of charge modification

 

 

FIXED ASSETS

 

  • Land
  • Buildings
  • Plant and equipment
  • Furniture and fixtures
  • Vehicles

 

 

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                           None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.59.65

UK Pound

1

Rs.99.21

Euro

1

Rs.82.39

 

 

INFORMATION DETAILS

 

Information Gathered by :

PLK

 

 

Analysis Done by :

KAR

 

 

Report Prepared by :

NTH

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

5

PAID-UP CAPITAL

1~10

5

OPERATING SCALE

1~10

5

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

5

--PROFITABILIRY

1~10

3

--LIQUIDITY

1~10

5

--LEVERAGE

1~10

5

--RESERVES

1~10

5

--CREDIT LINES

1~10

5

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

YES

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

TOTAL

 

43

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.